<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2022-08-09T01:21:55.740Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[<em>JAK2</em> V617f in chronic myeloid leukemia: driving force or passive bystander?]]></title>
        <id>pubmed:35938951</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35938951/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages]]></title>
        <id>pubmed:35931086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2...]]></summary>
        <author>
            <name>Isidoro Cobo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer: Slaying the 9-headed Hydra]]></title>
        <id>pubmed:35931318</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35931318/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies...]]></summary>
        <author>
            <name>J J Adashek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of inflammation-induced tumor plasticity during myeloid transformation]]></title>
        <id>pubmed:35924979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35924979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid...]]></summary>
        <author>
            <name>Anna Yeaton</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Zebrafish models of inflammation in hematopoietic development and disease]]></title>
        <id>pubmed:35923854</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35923854/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Zebrafish offer an excellent tool for studying the vertebrate hematopoietic system thanks to a highly conserved and rapidly developing hematopoietic program, genetic amenability, optical transparency, and experimental accessibility. Zebrafish studies have contributed to our understanding of hematopoiesis, a complex process regulated by signaling cues, inflammation being crucial among them. Hematopoietic stem cells (HSCs) are multipotent cells producing all the functional blood cells, including...]]></summary>
        <author>
            <name>Sarada Ketharnathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal germinal center B cells function as a niche for T-cell lymphoma]]></title>
        <id>pubmed:35921527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35921527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development, using mouse models and human samples. Among the two mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox× G17V RHOA...]]></summary>
        <author>
            <name>Manabu Fujisawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases]]></title>
        <id>pubmed:35914495</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914495/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mammalian genomes are methylated on carbon-5 of many cytosines, mostly in CpG dinucleotides. Methylation patterns are maintained during mitosis via DNMT1, and regulatory factors involved in processes that include histone modifications. Methylation in a sequence longer than CpG can influence the binding of sequence-specific transcription factors, thus affecting gene expression. 5-Methylcytosine deamination results in C-to-T transition. While some mutations are beneficial, most are not; so...]]></summary>
        <author>
            <name>Xiaodong Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluation of Clonal Hematopoiesis in Pediatric ADA-SCID Gene Therapy Participants]]></title>
        <id>pubmed:35914227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35914227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-08-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous stem cell transplant with gene therapy (ASCT-GT) provides curative therapy while reducing pre-transplant immune-suppressive conditioning and eliminating post-transplant immune suppression. Clonal hematopoiesis of indeterminate potential (CHIP)-associated mutations increase and telomere lengths (TL) shorten with natural aging and DNA damaging processes. It is possible that if CHIP is present before ASCT-GT, or mutagenesis occurs due to busulfan exposure, the HSCs carrying these somatic...]]></summary>
        <author>
            <name>Shanna L White</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial Deep Dive into Hematopoietic Stem Cell Dormancy: Not Much Glycolysis but Plenty of Sluggish Lysosomes]]></title>
        <id>pubmed:35908627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35908627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The discovery of hematopoietic stem cells (HSCs) heterogeneity have had major implications for investigations of hematopoietic stem cell disorders, clonal hematopoiesis and HSC aging. More recent studies of the heterogeneity of HSC organelles have begun to provide additional insights into the HSC behavior with far reaching ramifications for mechanistic understanding of aging of HSCs and stem cell-derived diseases. Mitochondrial heterogeneity has been explored to expose HSC subsets with distinct...]]></summary>
        <author>
            <name>Jiajing Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis]]></title>
        <id>pubmed:35899391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Lorenza Falini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma]]></title>
        <id>pubmed:35899825</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35899825/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this limited cohort of NB patients clinically informative tumor-associated mt and nuclear circulating variants were detected by targeted parallel sequencing in a minority of patients.]]></summary>
        <author>
            <name>Lara Riehl</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CAR T-cell Therapy Meets Clonal Hematopoiesis]]></title>
        <id>pubmed:35896010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al. (8).]]></summary>
        <author>
            <name>Ugur Uslu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications]]></title>
        <id>pubmed:35885563</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885563/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS...]]></summary>
        <author>
            <name>Yannick Simoni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Mesenchymal Niche in Myelodysplastic Syndromes]]></title>
        <id>pubmed:35885544</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885544/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology...]]></summary>
        <author>
            <name>Chloé Friedrich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease]]></title>
        <id>pubmed:35885518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid profiling uses circulating tumor DNA (ctDNA) for minimal invasive tumor mutational profiling from peripheral blood. The presence of somatic mutations in peripheral blood cells without further evidence of a hematologic neoplasm defines clonal hematopoiesis of indeterminate potential (CHIP). CHIP-mutations can be found in the cell-free DNA (cfDNA) of plasma, are a potential cause of false positive results in liquid profiling, and thus limit its usage in screening settings. Various...]]></summary>
        <author>
            <name>Gregor Hoermann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers]]></title>
        <id>pubmed:35885462</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35885462/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from...]]></summary>
        <author>
            <name>Jaja Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML]]></title>
        <id>pubmed:35896960</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35896960/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult...]]></summary>
        <author>
            <name>Sara J C Gosline</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge]]></title>
        <id>pubmed:35893374</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35893374/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Secondary acute myeloid leukemia can be divided into two categories: AML evolving from the antecedent hematological condition (AHD-AML) and therapy related AML (t-AML). AHD-AML can evolve from hematological conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, MDS/MPN overlap syndromes, Fanconi anemia, and aplastic anemia. Leukemic transformation occurs as a consequence of the clonal evolution-a process of the acquisition of mutations in clones, while previous mutations are...]]></summary>
        <author>
            <name>Paulina Stefaniuk</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing]]></title>
        <id>pubmed:35884979</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35884979/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives treatment failure in multiple myeloma (MM). Here, we used a custom 372-gene panel to track genetic changes occurring during MM progression at different stages of the disease. A tumor-only targeted next-generation DNA sequencing was performed on 69 samples sequentially collected from 30 MM patients. The MAPK/ERK pathway was mostly affected with KRAS mutated in 47% of patients. Acquisition and loss of mutations were observed in 63% and 37% of patients, respectively. Four...]]></summary>
        <author>
            <name>Aleksander Salomon-Perzyński</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Timing evolution of lobular breast cancer through phylogenetic analysis]]></title>
        <id>pubmed:35882101</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35882101/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood.]]></summary>
        <author>
            <name>Danai Fimereli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation]]></title>
        <id>pubmed:35877223</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35877223/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with...]]></summary>
        <author>
            <name>Peter A DeRosa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors]]></title>
        <id>pubmed:35876224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35876224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false...]]></summary>
        <author>
            <name>Mitsuho Imai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer]]></title>
        <id>pubmed:35872970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35872970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The pursuit of highly sensitive and specific cancer diagnostics based on cell-free (cf) nucleic acids isolated from minimally invasive liquid biopsies has been an area of intense research and commercial effort for at least two decades. Most of these tests detect cancer-specific mutations or epigenetic modifications on circulating DNA derived from tumor cells (ctDNA). Although recent FDA approvals of both single and multi-analyte liquid biopsy companion diagnostic assays are proof of the...]]></summary>
        <author>
            <name>Eddie Adams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Máire Ní Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Máire Ní Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Máire Ní Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Population genetics of clonally transmissible cancers]]></title>
        <id>pubmed:35879542</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35879542/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Populations of cancer cells are subject to the same core evolutionary processes as asexually reproducing, unicellular organisms. Transmissible cancers are particularly striking examples of these processes. These unusual cancers are clonal lineages that can spread through populations via physical transfer of living cancer cells from one host individual to another, and they have achieved long-term success in the colonization of at least eight different host species. Population genetic theory...]]></summary>
        <author>
            <name>Máire Ní Leathlobhair</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Discovering the drivers of clonal hematopoiesis]]></title>
        <id>pubmed:35871184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35871184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs) drive clonal hematopoiesis (CH). While some CH drivers have been identified, the compendium of all genes able to drive CH upon mutations in HSCs remains incomplete. Exploiting signals of positive selection in blood somatic mutations may be an effective way to identify CH driver genes, analogously to cancer. Using the tumor sample in blood/tumor pairs as reference, we identify blood somatic mutations across...]]></summary>
        <author>
            <name>Oriol Pich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk]]></title>
        <id>pubmed:35866704</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35866704/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients]]></title>
        <id>pubmed:35867969</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35867969/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs...]]></summary>
        <author>
            <name>Shukmei Wong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging]]></title>
        <id>pubmed:35858618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35858618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) mediate regeneration of the hematopoietic system following injury, such as following infection or inflammation. These challenges impair HSC function, but whether this functional impairment extends beyond the duration of inflammatory exposure is unknown. Unexpectedly, we observed an irreversible depletion of functional HSCs following challenge with inflammation or bacterial infection, with no evidence of any recovery up to 1 year afterward. HSCs from challenged...]]></summary>
        <author>
            <name>Ruzhica Bogeska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality]]></title>
        <id>pubmed:35857592</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35857592/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype,...]]></summary>
        <author>
            <name>Soichi Sano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hidden treasures: Incidental findings in two cases of chronic subdural hematoma]]></title>
        <id>pubmed:35855153</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855153/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: EMH is rare and usually found in individuals with profound and chronic anemia. However, this entity may be more common in chronic subdural hematomas. Solitary extraosseous plasmacytoma is exceedingly rare in the cranium, and its presence in chronic subdural hematoma membranes is of uncertain significance. The cytokine milieu that promotes organization of chronic subdural hematomas may play a role in the establishment of both of entities in this location.]]></summary>
        <author>
            <name>Alexander Ladenheim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetics of testicular cancer: a review]]></title>
        <id>pubmed:35855571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35855571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Testicular germ cell tumours (TGCTs) are the most common solid malignant cancer diagnosed in young males and the incidence is increasing. Understanding the genetic basis of this disease will help us to navigate the challenges of early detection, diagnosis, treatment, surveillance, and long-term outcomes for patients.]]></summary>
        <author>
            <name>Felicity C Martin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hypertension in Cancer Survivors]]></title>
        <id>pubmed:35852781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35852781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of...]]></summary>
        <author>
            <name>Mohammed Hasan Khan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma]]></title>
        <id>pubmed:35853232</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35853232/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups with distinct immunogenomic characteristics. Sparsely infiltrated tumors displayed active...]]></summary>
        <author>
            <name>Youpei Lin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Battles in the field of carcinogenesis]]></title>
        <id>pubmed:35850404</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35850404/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding...]]></summary>
        <author>
            <name>Zahraa Rahal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms]]></title>
        <id>pubmed:35844680</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35844680/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such as thrombocytosis or splenomegaly. Recent studies have better defined the genetics underlying this diverse group of disorders. Trisomy 8, monosomy 7, and loss of Y chromosome are the most common cytogenetic abnormalities seen. Chronic myelomonocytic leukemia (CMML) likely develops from early clones with TET2...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing]]></title>
        <id>pubmed:35840818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35840818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The role of next-generation sequencing (NGS) in identifying mutations in the driver, epigenetic regulator, RNA splicing, and signaling pathway genes in myeloproliferative neoplasms (MPNs) has contributed substantially to our understanding of the disease pathogenesis as well as disease evolution. NGS aids in determining the clonal nature of the disease in a subset of these disorders where mutations in the driver genes are not detected. There is a paucity of real-world data on the utility of this...]]></summary>
        <author>
            <name>Madhavi Maddali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis]]></title>
        <id>pubmed:35835912</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35835912/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell...]]></summary>
        <author>
            <name>Siddhartha P Kar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With <em>SF3B1</em> Mutation]]></title>
        <id>pubmed:35832562</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832562/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk...]]></summary>
        <author>
            <name>Liya Ma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma]]></title>
        <id>pubmed:35832612</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35832612/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although only a few recurrent somatic mutations have been identified, chromosomal abnormalities, including the loss of heterozygosity (LOH) at the chromosome 1p and gains of chromosome 17q, are often seen in the high-risk cases. The biological basis and evolutionary forces that drive such genetic abnormalities remain enigmatic. Here, we conceptualize the Gene Utility Model (GUM) that seeks to identify genes driving...]]></summary>
        <author>
            <name>Choong Y Ung</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220726212041&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pathophysiology of hematological malignancies associated with ASXL1 mutations]]></title>
        <id>pubmed:35831189</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831189/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has been linked to an increased risk of hematological malignancies. Therefore, ASXL1...]]></summary>
        <author>
            <name>Takeshi Fujino</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem Cells in the Myelodysplastic Syndromes]]></title>
        <id>pubmed:35822030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and is propagated by malignant stem cells (MDS-SCs), that arise due to the sequential acquisition of genetic and epigenetic alterations in normal hematopoietic stem cells (HSCs). This review focuses on recent advancements in the...]]></summary>
        <author>
            <name>Di Zhan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans]]></title>
        <id>pubmed:35821803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35821803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is characterized by increased mortality, functional decline, and exponential increases in the incidence of diseases such as cancer, stroke, cardiovascular disease, neurological disease, respiratory disease, etc. Though the role of aging in these diseases is widely accepted and considered to be a common denominator, the underlying mechanisms are largely unknown. A significant age-related feature observed in many population cohorts is somatic mosaicism, the detectable accumulation of somatic...]]></summary>
        <author>
            <name>Kenneth Walsh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220808212152&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220807211336&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220806211830&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220805210849&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220801212447&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220731212525&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220730212309&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220729211332&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220728211733&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia]]></title>
        <id>pubmed:35822488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35822488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The genetic architecture of cancer has been delineated through advances in high-throughput next-generation sequencing, where the sequential acquisition of recurrent driver mutations initially targeted towards normal cells ultimately leads to malignant transformation. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies frequently initiated by mutations in the normal hematopoietic stem cell compartment leading to the establishment of leukemic stem cells....]]></summary>
        <author>
            <name>Petter S Woll</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development]]></title>
        <id>pubmed:35831448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35831448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical risk groups. Favourable-risk disease sub-types assessed (MB(WNT) and infant desmoplastic/nodular MB(SHH)) typically comprised a single clone with no evidence of further evolution. In contrast, highest risk sub-classes (MYC-amplified MB(Group3) and...]]></summary>
        <author>
            <name>Marina Danilenko</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cardiovascular Disease in Myeloproliferative Neoplasms: <em>JACC: CardioOncology</em> State-of-the-Art Review]]></title>
        <id>pubmed:35818539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35818539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a...]]></summary>
        <author>
            <name>Orly Leiva</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220804212147&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220803212051&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220802212153&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pressure sculps tumor cells and trims high-quality mutations]]></title>
        <id>pubmed:35820396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35820396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.]]></summary>
        <author>
            <name>Michal Bassani-Sternberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220724211604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted sequencing of candidate gene regions for myelofibrosis in dogs]]></title>
        <id>pubmed:35815881</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815881/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND CLINICAL IMPORTANCE: Somatic variants might initiate or perpetuate myelofibrosis in dogs. Our findings suggest the occurrence of clonal hematopoiesis in dogs, with increasing incidence with age, as observed in humans.]]></summary>
        <author>
            <name>Amelia G Campbell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220727211458&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genetic analysis of histological components of combined small cell carcinoma]]></title>
        <id>pubmed:35815661</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35815661/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: We conclude that the morphological evolution of heterogeneous histological components in cSCLC may be associated with differences in ASCL1 expression levels, but not in acquired somatic gene mutations.]]></summary>
        <author>
            <name>Yuko Iida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD]]></title>
        <id>pubmed:35805204</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35805204/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic obstructive pulmonary disease (COPD) is a disease with an inflammatory phenotype with increasing prevalence in the elderly. Expanded population of mutant blood cells carrying somatic mutations is termed clonal hematopoiesis of indeterminate potential (CHIP). The association between CHIP and COPD and its relevant effects on DNA methylation in aging are mainly unknown. Analyzing the deep-targeted amplicon sequencing from 125 COPD patients, we found enhanced incidence of CHIP mutations...]]></summary>
        <author>
            <name>Stefan Kuhnert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[JAK inhibitors in the treatment of myelofibrosis]]></title>
        <id>pubmed:35802878</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35802878/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at...]]></summary>
        <author>
            <name>Hannah Levavi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms]]></title>
        <id>pubmed:35803921</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35803921/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are aggressive leukemia that develops as a complication of prior exposure to DNA-damaging agents. Clonal cytopenia of undetermined significance (CCUS) is a precursor of de novo myeloid neoplasms. Characteristics of CCUS that develop following cytotoxic therapies (therapy-related clonal cytopenia, t-CC) and outcomes following t-CC have not been described. We identified 33 patients with t-CC and compared to a cohort of the WHO-defined t-MN (n = 309). t-CC...]]></summary>
        <author>
            <name>Mithun Vinod Shah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:35797508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: cfDNA-based NGS profiling yielded low detection rates in this metastatic ccRCC cohort. Concordance with tumor profiling was low, even for truncal mutations such as VHL, and some findings in peripheral blood may represent clonal hematopoiesis. Routine cfDNA panel testing is not supported, and its application in biomarker efforts must account for these limitations.]]></summary>
        <author>
            <name>Ritesh R Kotecha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis]]></title>
        <id>pubmed:35795468</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35795468/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We reported two MDS/MPN-U and one CMML patients with CSF3R T618I mutation. There were two males and one female, with a median age of 84 years. Three patients presented with leukocytosis and anemia, two with thrombocytopenia, and one with monocytosis. In all the patients, bone marrow showed hypercellularity with myeloid or erythroid predominant trilineage hematopoiesis and dysplasia. Two cases carried -7/-7q abnormalities. In addition to CSF3R T618/I mutation, each case carried 3-5 additional...]]></summary>
        <author>
            <name>Xinmin Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit]]></title>
        <id>pubmed:35797509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35797509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study identified potential biomarkers of response to ICIs among patients with mTNBC: high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways. Pretreatment deficiencies in the homologous recombination DNA damage repair pathway and the absence of or minimal clonal evolution post-treatment may be associated with worse outcomes.]]></summary>
        <author>
            <name>Romualdo Barroso-Sousa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications, and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease-related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects]]></title>
        <id>pubmed:35788175</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788175/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) increases rapidly in prevalence beyond age 60 and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Because mutations in HSPCs often drive leukemia, we hypothesized that HSPC fitness substantially contributes to transformation from CHIP to leukemia. HSPC fitness is defined as the proliferative advantage over cells...]]></summary>
        <author>
            <name>Neil A Robertson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Role of p53 in regulation of hematopoiesis in health and disease]]></title>
        <id>pubmed:35787548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and serves as a reservoir for leukemic relapse. Somatic mutations in the TP53 gene, which encodes the tumor suppressor protein p53, rank in the top five among genes that were mutated in CHIP. TP53 mutations in CHIP are associated with an increased...]]></summary>
        <author>
            <name>Sergio Barajas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications]]></title>
        <id>pubmed:35787546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment.]]></summary>
        <author>
            <name>Florian Hagenbourger</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib]]></title>
        <id>pubmed:35787092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35787092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Introduction: Myelofibrosis, a life shortening clonal disorder, presents with a constellation of features: bone marrow fibrosis, abnormal blood counts, extramedullary hematopoiesis, splenomegaly, thrombohemorrhagic complications and constitutional symptoms. Until recently Ruxolitinib, a JAK1 and 2 inhibitor, has been the only targeted therapy available for transplant-ineligible patients requiring treatment for splenomegaly and disease related symptoms. However, most patients discontinue...]]></summary>
        <author>
            <name>Chandan Saha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current and emerging drugs for the treatment of atherosclerosis: the evidence to date]]></title>
        <id>pubmed:35786159</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35786159/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Atherosclerosis can be considered a chronic inflammatory process that stands out as a dominant cause of cardiovascular disease (CVD). Since blood lipids are the leading risk factor for atherosclerosis development, lowering low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins reduces the risk of future cardiovascular events. However, there has been significant progress in developing lipid-lowering drugs for aggressive management of...]]></summary>
        <author>
            <name>Ali A Rizvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220726212040&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220725211845&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220724211605&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220723212121&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220722211347&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research]]></title>
        <id>pubmed:35788590</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35788590/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell analysis methods are valuable tools; however, current approaches do not easily enable live cell retrieval. That is a particular issue when further study of cells that were eliminated during experimentation could provide critical information. We report a clonal molecular barcoding method, called SunCatcher, that enables longitudinal tracking and live cell functional analysis. From complex cell populations, we generate single cell-derived clonal populations, infect each with a unique...]]></summary>
        <author>
            <name>Qiuchen Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell sequencing reveals CD133<sup>+</sup>CD44<sup>-</sup>-originating evolution and novel stemness related variants in human colorectal cancer]]></title>
        <id>pubmed:35785618</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35785618/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Tumor heterogeneity of human colorectal cancer (CRC)-initiating cells (CRCICs) in cancer tissues often represents aggressive features of cancer progression. For high-resolution examination of CRCICs, we performed single-cell whole-exome sequencing (scWES) and bulk cell targeted exome sequencing (TES) of CRCICs to investigate stemness-specific somatic alterations or clonal evolution.]]></summary>
        <author>
            <name>Xiaoyan Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms]]></title>
        <id>pubmed:35781188</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35781188/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-07-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: While DDX41 mutation (m) is one of the most prevalent predisposition genes in adult myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), most patients do not always present with a family history of MDS/AML. In this review, we will be highlighting epidemiological data on DDX41m, roles of DDX41 in oncogenesis, mechanisms of clonal evolution with somatic DDX41m, and clinical phenotypes and management of MDS/AML in patients harboring DDX41m.]]></summary>
        <author>
            <name>Talha Badar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220721211948&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220720211338&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220719211909&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220718212208&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?]]></title>
        <id>pubmed:35772431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic inflammatory and autoimmune diseases and myelodysplastic syndromes have been linked in individual patients and in larger case series for at least 25 years. These associations frequently include thyroid disease, neutrophilic dermatoses, polyarthritis, connective tissue diseases, vasculitis, and autoimmune cytopenias. Studies have found that autoimmune disease (or its therapy) is a risk factor for the development of myelodysplastic syndromes, but such syndromes might also be an instigator...]]></summary>
        <author>
            <name>Michael J Hochman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients]]></title>
        <id>pubmed:35772351</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35772351/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.]]></summary>
        <author>
            <name>Francesca Bagnasco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms]]></title>
        <id>pubmed:35771847</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35771847/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic inflammation is considered a major driving force for clonal expansion and evolution in the Philadelphia-negative myeloproliferative neoplasms, which include essential thrombocythemia, polycythemia vera and primary myelofibrosis (MPNs). One of the key mutation drivers is the JAK2V617F mutation, which has been shown to induce the generation of reactive oxygen species (ROS). Using whole blood gene expression profiling, deregulation of several oxidative stress and anti-oxidative defense...]]></summary>
        <author>
            <name>Vibe Skov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[To B- or not to B-: A review of lineage switched acute leukemia]]></title>
        <id>pubmed:35770493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35770493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute leukemia is a heterogeneous disorder of hematologic malignancies composed primarily of hematopoietic precursors that have acquired unregulated self-renewal and proliferation. Hematology classification systems typically divide these neoplasms into lymphoid (B- or T-) and myeloid-lineage subtypes, with therapy dependent upon this distinction. Infrequently, certain acute leukemias may undergo a complete lineage switch at relapse, subsequently complicating the diagnosis and treatment of these...]]></summary>
        <author>
            <name>Jason H Kurzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220717211412&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220716212224&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive Analysis of Intratumoural Heterogeneity of Somatic Copy Number Alterations in Diffuse Glioma Reveals Clonality-dependent Prognostic Patterns]]></title>
        <id>pubmed:35767937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35767937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.]]></summary>
        <author>
            <name>Shangyi Luo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo]]></title>
        <id>pubmed:35764632</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35764632/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[High transduction rates of viral vectors in gene therapies (GT) and experimental hematopoiesis ensure a high frequency of gene delivery, although multiple integration events can occur in the same cell. Therefore, tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in GT. Hence, we use correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for...]]></summary>
        <author>
            <name>Sebastian Wagner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220715211735&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220714212604&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reconstructing tumor clonal lineage trees incorporating single-nucleotide variants, copy number alterations and structural variations]]></title>
        <id>pubmed:35758777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35758777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: Cancer develops through a process of clonal evolution in which an initially healthy cell gives rise to progeny gradually differentiating through the accumulation of genetic and epigenetic mutations. These mutations can take various forms, including single-nucleotide variants (SNVs), copy number alterations (CNAs) or structural variations (SVs), with each variant type providing complementary insights into tumor evolution as well as offering distinct challenges to phylogenetic...]]></summary>
        <author>
            <name>Xuecong Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma]]></title>
        <id>pubmed:35753868</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35753868/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) refers to the disproportionate expansion of hematopoietic stem cell clones and their corresponding progeny following the acquisition of somatic mutations. CH is common at the time of diagnosis in patients with blood cancers, including multiple myeloma (MM) and lymphoma. The presence of CH mutations correlates with IL-6 mediated inflammation and may result in lymphoma or MM modulation through microenvironment effects or by manifestations of the mutations themselves...]]></summary>
        <author>
            <name>Jeremy Meier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome]]></title>
        <id>pubmed:35752705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35752705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), defined as the presence of somatic mutations in cancer-related genes in blood cells in the absence of hematological cancer, has recently emerged as an important risk factor for several age-related conditions, especially cardiovascular disease. CHIP is strongly associated with normal aging, but its role in premature aging syndromes is unknown. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition driven by the...]]></summary>
        <author>
            <name>Miriam Díez-Díez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220713211901&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling]]></title>
        <id>pubmed:35751806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in genetically heterogeneous tumor cell populations using next-generation sequencing remains challenging. We have developed MuSE, Mutation calling using a Markov Substitution model for Evolution, a novel approach for modeling the evolution of the allelic composition of tumor and normal tissue at each reference base. It adopts a sample-specific error model to depict inter-tumor heterogeneity, which greatly improves the overall accuracy. Here, we describe...]]></summary>
        <author>
            <name>Shuangxi Ji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms]]></title>
        <id>pubmed:35751752</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35751752/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT.]]></summary>
        <author>
            <name>Mia J Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test]]></title>
        <id>pubmed:35741030</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741030/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of...]]></summary>
        <author>
            <name>Damien Vasseur</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220712211231&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool]]></title>
        <id>pubmed:35741115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35741115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for measuring gene expression, doing clonality assays and detecting hot spot mutations. In respect of QT-PCR, ddPCR is more sensitive, does not need any reference curve and can quantify one quarter of samples already defined as "positive but not quantifiable". In the IgH and TCR clonality assessment, ddPCR recapitulates the allele-specific oligonucleotide PCR (ASO-PCR), being not adapt for detecting clonal...]]></summary>
        <author>
            <name>Sara Galimberti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair]]></title>
        <id>pubmed:35740616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BRCA1 and BRCA2 are the most recognized tumor-suppressor genes involved in double-strand DNA break repair through the homologous recombination (HR) system. Widely known for its role in hereditary cancer, HR deficiency (HRD) has turned out to be critical beyond breast and ovarian cancer: for prostate and pancreatic cancer also. The relevance for the identification of these patients exceeds diagnostic purposes, since results published from clinical trials with poly-ADP ribose polymerase (PARP)...]]></summary>
        <author>
            <name>Vilma Pacheco-Barcia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study]]></title>
        <id>pubmed:35740343</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35740343/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted...]]></summary>
        <author>
            <name>Antonella Colosini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predicting the likelihood of a <em>BRCA1/2</em> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer]]></title>
        <id>pubmed:35738887</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35738887/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program]]></title>
        <id>pubmed:35734926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35734926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by...]]></summary>
        <author>
            <name>Keren Isaev</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220711211933&amp;v=2.17.7"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis]]></title>
        <id>pubmed:35730391</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730391/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH was more common in PLWH and among PLWH was associated with the extent of coronary artery disease. Larger studies are needed to further examine the biological and clinical consequences of CH in PLWH.]]></summary>
        <author>
            <name>Shiyu Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to study the evolution of somatic mutational processes in cancer]]></title>
        <id>pubmed:35732905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35732905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer cell genomes change continuously due to mutations, and mutational processes change over time in patients, leaving dynamic signatures in the accumulated genomic variation in tumors. Many computational methods detect the relative activities of known mutation signatures. However, these methods may produce erroneous signatures when applied to individual branches in cancer cell phylogenies. Here, we show that the inference of branch-specific mutational signatures can be improved through a...]]></summary>
        <author>
            <name>Sayaka Miura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Treatment represents a key driver of metastatic cancer evolution]]></title>
        <id>pubmed:35731928</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35731928/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastasis is the main cause of cancer death, yet the evolutionary processes behind it remain largely unknown. Here, through analysis of large panel-based genomic datasets from the AACR GENIE project, including 40,979 primary and metastatic tumors across 25 distinct cancer types, we explore how the evolutionary pressure of cancer metastasis shapes the selection of genomic drivers of cancer. The most commonly affected genes were TP53, MYC, and CDKN2A, with no specific pattern associated with...]]></summary>
        <author>
            <name>Ditte Sigaard Christensen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease]]></title>
        <id>pubmed:35730597</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35730597/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results highlight a key role of activated HIF2α due to mutated EPAS1 in positive selection under hypoxic environments, although hypoxemia itself may not necessarily be required for the EPAS1-mutated clones to progress to PPGL.]]></summary>
        <author>
            <name>Tatsuki Ogasawara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220710211548&amp;v=2.17.7"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220709212311&amp;v=2.17.7"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease]]></title>
        <id>pubmed:35726685</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726685/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging represents the major risk factor for the development of cancer and many other diseases. Recent findings show that normal tissues become riddled with expanded clones that are frequently driven by cancer-associated mutations in an aging-dependent fashion. Additional studies show how aged tissue microenvironments promote the initiation and progression of malignancies, while young healthy tissues actively suppress the outgrowth of malignant clones. Here, we discuss conserved mechanisms that...]]></summary>
        <author>
            <name>Fabio Marongiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:35726693</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35726693/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We...]]></summary>
        <author>
            <name>Mireia Ramos-Muntada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues]]></title>
        <id>pubmed:35725896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35725896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent research on normal human tissues identified omnipresent clones of cells, driven by somatic mutations known to be responsible for carcinogenesis (e.g., in TP53 or NOTCH1). These new insights are fundamentally changing current tumor evolution models, with broad oncological implications. Most studies are based on surgical remnant tissues, which are not available for many organs and rarely in a pan-organ setting (multiple organs from the same individual). Here, we describe an approach based...]]></summary>
        <author>
            <name>Tom Luijts</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220708210406&amp;v=2.17.7"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation]]></title>
        <id>pubmed:35724849</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35724849/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Although the underlying cellular and molecular mechanisms remain to be characterized in further detail, these data clearly demonstrate the impact of in-patient AF manifestation/AFiH on long-term outcome of SCT patients.]]></summary>
        <author>
            <name>Catherina Lueck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220707211901&amp;v=2.17.7"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Therapy-Related Clonal Hematopoiesis: A New Link Between Cancer and Cardiovascular Disease]]></title>
        <id>pubmed:35718411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35718411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a precancerous state that is recognized as a new causal risk factor for cardiovascular disease. Therapy-related clonal hematopoiesis is a condition that is often found in cancer survivors. These clonal expansions are caused by mutations in DNA damage-response pathway genes that allow hematopoietic stem cells to undergo positive selection in response to the genotoxic stress. These mutant cells increasingly give rise to progeny leukocytes that display enhanced...]]></summary>
        <author>
            <name>Yoshimitsu Yura</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220706212003&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TET2-mutant clonal hematopoiesis and risk of gout]]></title>
        <id>pubmed:35714308</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714308/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia. Acute flares are accompanied by secretion of pro-inflammatory cytokines, including interleukin-1 beta (IL-1B). Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. CHIP is associated with elevated IL-1B, thus we investigated CHIP as a risk factor for gout. To test the...]]></summary>
        <author>
            <name>Mridul Agrawal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions]]></title>
        <id>pubmed:35714307</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35714307/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult...]]></summary>
        <author>
            <name>Tae-Hoon Shin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220705212255&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow hematopoiesis drives multiple sclerosis progression]]></title>
        <id>pubmed:35709748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35709748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals...]]></summary>
        <author>
            <name>Kaibin Shi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)]]></title>
        <id>pubmed:35710421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35710421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our HGE-scSeq data reveals high heterogeneity of HCC tumor cells in terms of both HBV integrations and CNVs. There were two HBV integration hotspots across cells, and cells from multiple tumor sites shared some HBV integration and CNV patterns.]]></summary>
        <author>
            <name>Wenhui Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lifelong multilineage contribution by embryonic-born blood progenitors]]></title>
        <id>pubmed:35705805</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705805/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Haematopoietic stem cells (HSCs) arise in the embryo from the arterial endothelium through a process known as the endothelial-to-haematopoietic transition (EHT)^(1-4). This process generates hundreds of blood progenitors, of which a fraction go on to become definitive HSCs. It is generally thought that most adult blood is derived from those HSCs, but to what extent other progenitors contribute to adult haematopoiesis is not known. Here we use in situ barcoding and classical fate mapping to...]]></summary>
        <author>
            <name>Sachin H Patel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation]]></title>
        <id>pubmed:35705990</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35705990/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results demonstrate that iPSCs with homozygous knockout of different exons of DNMT3A remain capable of mesenchymal and hematopoietic differentiation-and exon 23^(-/-) iHPCs even gained growth advantage-despite loss of almost the entire de novo DNA methylation. Partial recapitulation of DNA methylation patterns of AML with DNMT3A mutations by our DNMT3A knockout iHPCs indicates that our model system can help to elucidate mechanisms of clonal hematopoiesis.]]></summary>
        <author>
            <name>Olivia Cypris</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors]]></title>
        <id>pubmed:35704087</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35704087/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The most frequent CHIP-related mutations, DNMT3A, TET2, and ASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.]]></summary>
        <author>
            <name>Zaixin Jiang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma]]></title>
        <id>pubmed:35703914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35703914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Composite pleomorphic xanthoastrocytoma-ganglioglioma (PXA-GG) is an extremely rare central nervous system neoplasm with 2 distinct but intermingled components. Whether this tumor represents a "collision tumor" of separate neoplasms or a monoclonal neoplasm with divergent evolution is poorly understood. Clinicopathologic studies and capture-based next generation sequencing were performed on extracted DNA from all available PXA-GG at 2 medical centers. Five PXA-GG were diagnosed in 1 male and 4...]]></summary>
        <author>
            <name>Calixto-Hope G Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220704211122&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220703212221&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220702211519&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220701211233&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220630212102&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629210920&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220629090955&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220628211035&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220627211523&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220614211251&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[What constitutes meaningful improvement in myelodysplastic syndromes?]]></title>
        <id>pubmed:35699987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35699987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220614211251&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of...]]></summary>
        <author>
            <name>Namrata S Chandhok</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis]]></title>
        <id>pubmed:35700150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Clonal hematopoiesis is the production of a specific single clonal type of cell in the blood and is often found in cancer genomic profiling tests. When the clone carries a pathogenic variant, it may be important to differentiate between somatic or germline origin. The variant in the blood that has a lower minor allele frequency could reflect heterozygous germline origin, somatic mosaicism, and clonal hematopoiesis. It is important to evaluate suspected variants to determine the course...]]></summary>
        <author>
            <name>Miki Kawai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dysplastic stem cell plasticity functions as a driving force for neoplastic transformation of pre-cancerous gastric mucosa]]></title>
        <id>pubmed:35700772</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35700772/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These findings indicate that the DSCs are de novo gastric cancer-initiating cells responsible for neoplastic transformation and a promising target for intervention in early induction of gastric cancer.]]></summary>
        <author>
            <name>Jimin Min</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626212149&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220626131729&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220625211446&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220624210923&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220614211251&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220614211251&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes]]></title>
        <id>pubmed:35695283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35695283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220613211945&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inhibitors of poly (ADP-ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In this study, of 182 women with EOC treated with PARPi, 16 (8.7%) developed therapy-related myeloid neoplasms (t-MNs), with 12 cases of myelodysplasia and 4 of acute myeloid leukemia. All experienced persistent cytopenia after PARPi discontinuation. Seven...]]></summary>
        <author>
            <name>Elisabetta Todisco</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in clinical practice: walking a tightrope]]></title>
        <id>pubmed:35694869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35694869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20220613211945&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The understanding of clonal hematopoiesis (CH) and its features is rapidly evolving in step with the spread of sequencing techniques. Indeed, CH detection is now an emerging aspect in clinical practice. The awareness of CH intersects with consolidated diagnostic paths, thus exposing 'grey zone' circumstances under the magnifying lens of clinicians. The interpretation of genomic data poses, in some cases, a true clinical challenge, sometimes further complicating the route to diagnosis. The line...]]></summary>
        <author>
            <name>Francesco Tarantini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220623210756&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220622210352&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220621212000&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220620211049&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220619211253&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220618211120&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220617210912&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220616210436&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220615211026&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response]]></title>
        <id>pubmed:35697558</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/35697558/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20220614211251&amp;v=2.17.6"/>
        <updated>2022-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Lung cancers account for over 90% of thoracic malignancies and the rapid development of specific cytotoxic drugs and molecular therapies requires a detailed identification of the different histologies, gene drivers or immune microenvironment biomarkers. Nevertheless, the heterogeneous clonal evolution, the emergency of drug-induced resistance and the limited occurrence of genetic alterations claim the need of a deep integration of the tumor's and the patient's biological features. The aim of the...]]></summary>
        <author>
            <name>Paolo Bironzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
— NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.⏰Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
⏰Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
— VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻💌]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻
💌 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️ https://t.co/qWH2dTv8j9
— Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
— NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
— NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
— NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻 https://t.co/VbyoUJmTRJ
— NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
— Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.💌]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
💌 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
— NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
— Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.📯]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
📯 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
— NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
— NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>